World Desk, Amar Ujala, Washington
Updated Wed, 18 Nov 2020 09:57 PM IST
– Photo: Amar Ujala (File)
Listen to the news
The Phase 3 study of our #COVID19 vaccine candidate has met all primary efficacy endpoints. The study reached 170 confirmed cases of COVID19, with the vaccine candidate BNT162b2 demonstrating 95% efficacy beginning 28 days after the first dose: Pfizer Inc pic.twitter.com/iNYjAXGUHv
– ANI (@ANI) November 18, 2020
Pfizer and Bio-Entech, the world’s leading pharmaceutical companies, said on Wednesday that the potential vaccine for the Kovid-19 they are producing is up to 95 percent effective and is effective even for people over 65 years of age. Dr. Albert Burla, President and Chief Executive Officer of Pfizer said that hundreds of people are getting infected everyday in the world and we urgently need an effective vaccine. Burla said, ‘The results of this study have made a significant breakthrough in the eight-month journey. We are engaged in the manufacture of vaccines to end this deadly epidemic. We are following the pace of science and are sharing all the data collected so far with regulators around the world.
Pfizer and Bio-Entech stated that they have completed the Phase III study of the mRNA-based potential vaccine ‘BNT162B2’ of Kovid-19. Based on current estimates, companies are expected to produce 50 million doses of the vaccine globally by 2020, and by the end of 2021, the production could reach 130 million doses. Two days before this, the Moderna company announced that the vaccine produced by it is 94.5 percent effective.